J I Johnson

2.6k total citations · 2 hit papers
7 papers, 2.0k citations indexed

About

J I Johnson is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, J I Johnson has authored 7 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 1 paper in Pharmacology. Recurrent topics in J I Johnson's work include Cancer-related Molecular Pathways (2 papers), Cancer therapeutics and mechanisms (1 paper) and Fungal Plant Pathogen Control (1 paper). J I Johnson is often cited by papers focused on Cancer-related Molecular Pathways (2 papers), Cancer therapeutics and mechanisms (1 paper) and Fungal Plant Pathogen Control (1 paper). J I Johnson collaborates with scholars based in United States and Malaysia. J I Johnson's co-authors include Edward A. Sausville, Vito J. Palombella, Christine Pien, Julian Adams, Peter J. Elliott, Douglas Lazarus, Jochen Maas, Antonia T. Destree, Daniel Zaharevitz and John M. Venditti and has published in prestigious journals such as Annals of the New York Academy of Sciences, Journal of Medicinal Chemistry and British Journal of Cancer.

In The Last Decade

J I Johnson

7 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 1.2k citations Julian Adams, Vito J. Palombella et al. PubMed profile →
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

2001 621 citations J I Johnson, Shannon Decker et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J I Johnson United States	7	1.3k	853	359	316	187	7	2.0k
Muthu Selvakumaran United States	22	1.3k 1.0×	745 0.9×	160 0.4×	339 1.1×	95 0.5×	31	1.9k
William E. Pierceall United States	25	1.4k 1.1×	1.1k 1.3×	371 1.0×	351 1.1×	148 0.8×	55	2.5k
Douglas W. McMillin United States	25	1.2k 0.9×	837 1.0×	642 1.8×	263 0.8×	163 0.9×	57	2.1k
Simona Ronzoni Italy	17	2.2k 1.7×	1.3k 1.6×	401 1.1×	659 2.1×	206 1.1×	29	3.2k
David F. Carmichael United States	16	1.4k 1.1×	720 0.8×	189 0.5×	645 2.0×	193 1.0×	23	2.4k
Alexander R. Shoemaker United States	19	2.2k 1.7×	906 1.1×	233 0.6×	311 1.0×	124 0.7×	22	3.0k
Rachael E. Hawtin United States	18	1.3k 1.0×	645 0.8×	170 0.5×	237 0.8×	82 0.4×	53	2.0k
Kristina Viktorsson Sweden	27	1.5k 1.2×	637 0.7×	151 0.4×	469 1.5×	182 1.0×	70	2.2k
Béatrice Eymin France	33	2.3k 1.8×	991 1.2×	126 0.4×	546 1.7×	231 1.2×	59	2.9k
Minji Jo United States	23	1.6k 1.2×	796 0.9×	239 0.7×	902 2.9×	216 1.2×	33	2.5k

Countries citing papers authored by J I Johnson

Since Specialization

Citations

This map shows the geographic impact of J I Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J I Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J I Johnson more than expected).

Fields of papers citing papers by J I Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J I Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J I Johnson. The network helps show where J I Johnson may publish in the future.

Co-authorship network of co-authors of J I Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of J I Johnson. A scholar is included among the top collaborators of J I Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J I Johnson. J I Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Johnson, J I, Shannon Decker, Daniel Zaharevitz, et al.. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer. 84(10). 1424–1431. 621 indexed citations breakdown →

2.

Mu, Fanrong, Stephanie L. Coffing, David J. Riese, et al.. (2001). Design, Synthesis, and Biological Evaluation of a Series of Lavendustin A Analogues That Inhibit EGFR and Syk Tyrosine Kinases, as Well as Tubulin Polymerization. Journal of Medicinal Chemistry. 44(3). 441–452. 38 indexed citations

3.

Sausville, Edward A. & J I Johnson. (2000). Molecules for the millennium: how will they look? New drug discovery year 2000. British Journal of Cancer. 83(11). 1401–1404. 16 indexed citations

4.

Sausville, Edward A., J I Johnson, Michael C. Alley, Daniel Zaharevitz, & Adrian M. Senderowicz. (2000). Inhibition of CDKs as a Therapeutic Modality. Annals of the New York Academy of Sciences. 910(1). 207–222. 66 indexed citations

5.

Adams, Julian, Vito J. Palombella, Edward A. Sausville, et al.. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents.. PubMed. 59(11). 2615–22. 1188 indexed citations breakdown →

6.

Kunkel, Mark W., David Kirkpatrick, J I Johnson, & Garth Powis. (1997). Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.. PubMed. 12(8). 659–70. 46 indexed citations

7.

Newman, Robert A., et al.. (1993). VRCTC-310 — A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity. Investigational New Drugs. 11(2-3). 151–159. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact